

MIMESIS

NEWSLETTER #4 / DECEMBER 2018


ENYO
P H A R M A

ENYO Pharma's EU funded MIMESIS project has delivered several new drug development starting points most significantly for RSV and ICD (Immunogenic Cell Death).

With 3.6 million euros spending over 24 months, ENYO Pharma's drug discovery approach has delivered hits in all phenotypic screens. Five novel scaffolds have been optimized into promising leads developable for several indications with unmet medical needs.



MIMESIS' scientific achievements



Validated approach

The 6 phenotypic screens delivered hits



Validated library


Numerous potent molecules



Lead molecules

Target deconvolution and first ongoing *in vivo* data


MIMESIS, ready for partnerships!



An incredible success supports the relevance of our approach



BD discussion in progress with big pharmas



2 most advanced programs: ICD and RSV

In vivo data and mode of action under validation

MIMESIS



Projects are continuing beyond the EU program

LET'S DISCUSS!

Conclusion

The MIMESIS small molecule library, inspired by viral strategies to modulate host cell biology, is a unique compound collection. It is enriched with a higher than expected percentage of active molecules and offers a pioneering and disruptive technology to identify new starting points for drug candidates in infectious diseases and oncology. The approach has delivered several hits, two of them being currently developed by ENYO Pharma. We are open to partnerships to co-develop the other promising one.

We warmly thank the whole staff of EIC SME Instrument for their valuable input and more specifically our project officer for all her support.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement n° 739086-MIMESIS.

Contact: Jacky Vonderscher, CEO / Eric Meldrum, CSO

mimesis@enyopharma.com

FOLLOW US ON: www.enyopharma.com

